Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06852469 · ClinicalTrials.gov registry record · Phase 4
Computational Assessment of GABA Receptor Modulation in PTSD
A Phase 4 study of Stress Disorders, Post-Traumatic, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT06852469: Recruiting Phase 4 study of Stress Disorders, Post-Traumatic, sponsored by VA Office of Research and Development.
NCT06852469 is a Phase 4 study of Stress Disorders, Post-Traumatic that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 150 participants, roughly in line with the 154-participant average among 66 other Stress Disorders, Post-Traumatic trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06852469, a Phase 4 study of Stress Disorders, Post-Traumatic, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
A substantial majority of Veterans with posttraumatic stress disorder (PTSD) continue to suffer even with the best current medications. Progress in developing more effective medications is hampered by the substantial variability within Veterans with PTSD, meaning the most effective medication likely varies from individual to individual. New scientific tools to help identify distinct subgroups of Veterans with PTSD who are likely to respond to specific medications could help improve treatment in this population. Research has indicated that a specific subgroup of Veterans with PTSD with a high level of anxious arousal may benefit from medications which boost signaling of the neurotransmitter gamma-aminobutyric acid (GABA). This project aims to validate a clinical test to identify these individuals using new computational and neuroimaging methods combined with the medication lorazepam, a positive GABA modulator. The ultimate goal is to use these methods in future clinical trials of new medications to target the best treatments to individual Veterans with PTSD.
Primary Outcome
A dynamic inhibition parameter will be computed for each participant and session using a proportional-derivative (PD) model of sensorimotor control performance on the rapid assessment of motor processing (RAMP) task.
Conditions Studied
Interventions
- DRUG Placebo tablet
- DRUG Lorazepam 1 mg tablet
Study Locations (1)
California
- VA San Diego Healthcare System, San Diego, CA - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 4 |
What NCT06852469 shows while recruiting
NCT06852469 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 154-participant average among 66 other Stress Disorders, Post-Traumatic trials with a reported enrollment target.
The record links to 1 condition, with Stress Disorders, Post-Traumatic appearing as the primary indexed condition, and to 2 interventions - of which Placebo tablet is the first listed.
NCT06852469 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06852469 about?
NCT06852469 is a clinical study titled "Computational Assessment of GABA Receptor Modulation in PTSD". A substantial majority of Veterans with posttraumatic stress disorder (PTSD) continue to suffer even with the best current medications. Progress in developing more effective medications is hampered by the substantial variability within Veterans with PTSD, meaning the most effective medication likely...
What is the current status of trial NCT06852469?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2025-07-01. Estimated completion is 2029-06-30.
What conditions does trial NCT06852469 study?
This clinical trial studies the following conditions: Stress Disorders, Post-Traumatic.
What interventions are being tested in trial NCT06852469?
The interventions under investigation include: Placebo tablet (DRUG), Lorazepam 1 mg tablet (DRUG).
Who is sponsoring clinical trial NCT06852469?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06852469 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stress Disorders, Post-Traumatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06852469's enrollment target sits among peer trials
150 20th of 66 higher than 46 of 66 other Stress Disorders, Post-Traumatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stress Disorders, Post-Traumatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mismatch vs. Standard Intervention During Memory Reconsolidation Blockade With Propranolol: Effect on Psychophysiological Reactivity During Traumatic Imagery
RECRUITING · Phase 4
-
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
RECRUITING · Phase 4
-
CPT-SMART for Treatment of PTSD and Cigarette Smoking
COMPLETED · Phase 4
-
Manage Emotions to Reduce Aggression (MERA)
RECRUITING · NA
-
SMART Therapist Training: A Hybrid Factorial-SMART Design
RECRUITING · NA
-
Overcontrol and Suicide in PTSD
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI